Sale!

cKIT Mutation Screening Exons 9 11 13 17 Gastrointestinal Stromal Tumors Test Cost

Name: cKIT Mutation Screening Exons 9 11 13 17 Gastrointestinal Stromal Tumors Test Cost
SKU: TEST-4797
Price: 2400 AED
Availability: InStock

Original price was: 3,200 د.إ.Current price is: 2,400 د.إ.

-25%

The “cKIT Mutation Screening Exons 9, 11, 13, 17 Gastrointestinal Stromal Tumors Test” is a specialized diagnostic procedure available at DNA Labs UAE, designed to detect mutations in specific exons (9, 11, 13, and 17) of the cKIT gene. These mutations are critically important in the context of gastrointestinal stromal tumors (GISTs), as they can influence both the prognosis and the therapeutic approach for patients. GISTs are a type of tumor that occurs in the digestive tract, and the presence of cKIT mutations can make them responsive to targeted therapies, improving patient outcomes.

The test involves collecting a tissue sample from the tumor, which is then analyzed using advanced molecular techniques to identify any genetic alterations in the specified exons of the cKIT gene. This precision approach allows for a more tailored treatment plan, which could include targeted therapies specifically designed to address the identified mutations.

Offered at a cost of 2400 AED, this test represents a critical step for patients diagnosed with GIST, providing them with essential information that can guide their treatment plan. DNA Labs UAE is equipped with state-of-the-art facilities and employs highly skilled professionals to ensure accurate and reliable test results, contributing to better management and outcomes for GIST patients.

Description

cKIT Mutation Screening Exons 9 11 13 17 Gastrointestinal Stromal Tumors Test

Test Name: cKIT Mutation Screening Exons 9 11 13 17 Gastrointestinal Stromal Tumors Test

Components: Paraffin embedded tissue blocks

Price: 2400.0 AED

Sample Condition: Tumor tissue

Report Delivery: 7-8 days

Method: Sanger Sequencing

Test Type: Genetics

Doctor: Gynecologist

Test Department: Pre Test Information

Pre Test Information: cKIT Mutation Screening (Exons 9, 11, 13, 17) Gastrointestinal Stromal Tumors can be done with a Doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details:

KIT mutation screening is a diagnostic test used to detect mutations in the KIT gene in gastrointestinal stromal tumors (GISTs). GISTs are a type of tumor that originates in the gastrointestinal tract, particularly in the stomach or small intestine. The KIT gene provides instructions for making a protein called KIT receptor, which plays a crucial role in the growth and survival of certain cells, including the cells of the gastrointestinal tract. Mutations in the KIT gene can lead to the overactivation of the KIT receptor, causing uncontrolled cell growth and the development of GISTs.

The screening test focuses on specific regions of the KIT gene, including exons 9, 11, 13, and 17. Exons are the coding regions of genes that contain the instructions for making proteins. Mutations in these exons have been found to be common in GISTs and are associated with the development and progression of the tumors.

The screening process typically involves obtaining a tissue sample from the tumor through a biopsy or surgical procedure. The DNA from the sample is then analyzed using various techniques, such as polymerase chain reaction (PCR) or next-generation sequencing (NGS), to identify any mutations in the KIT gene.

The results of the screening test can help guide treatment decisions for patients with GISTs. Some KIT mutations have been found to be sensitive to specific targeted therapies, such as imatinib, which can inhibit the overactive KIT receptor and slow down the growth of the tumor.

Overall, KIT mutation screening is an important tool in the diagnosis and management of GISTs, allowing for personalized treatment approaches based on the specific genetic characteristics of the tumor.

Test Name	cKIT Mutation Screening Exons 9 11 13 17 Gastrointestinal Stromal Tumors Test
Components	Paraffin embedded tissue blocks
Price	2400.0 AED
Sample Condition	Tumors tissue
Report Delivery	7-8 days
Method	Sanger Sequencing
Test type	Genetics
Doctor	Gynecologist
Test Department:
Pre Test Information	cKIT Mutation Screening (Exons 9, 11, 13, 17) Gastrointestinal Stromal Tumors can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details	KIT mutation screening is a diagnostic test used to detect mutations in the KIT gene in gastrointestinal stromal tumors (GISTs). GISTs are a type of tumor that originates in the gastrointestinal tract, particularly in the stomach or small intestine. The KIT gene provides instructions for making a protein called KIT receptor, which plays a crucial role in the growth and survival of certain cells, including the cells of the gastrointestinal tract. Mutations in the KIT gene can lead to the overactivation of the KIT receptor, causing uncontrolled cell growth and the development of GISTs. The screening test focuses on specific regions of the KIT gene, including exons 9, 11, 13, and 17. Exons are the coding regions of genes that contain the instructions for making proteins. Mutations in these exons have been found to be common in GISTs and are associated with the development and progression of the tumors. The screening process typically involves obtaining a tissue sample from the tumor through a biopsy or surgical procedure. The DNA from the sample is then analyzed using various techniques, such as polymerase chain reaction (PCR) or next-generation sequencing (NGS), to identify any mutations in the KIT gene. The results of the screening test can help guide treatment decisions for patients with GISTs. Some KIT mutations have been found to be sensitive to specific targeted therapies, such as imatinib, which can inhibit the overactive KIT receptor and slow down the growth of the tumor. Overall, KIT mutation screening is an important tool in the diagnosis and management of GISTs, allowing for personalized treatment approaches based on the specific genetic characteristics of the tumor.